A Phase 1, Open-label, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Vanzacaftor/Tezacaftor/Deutivacaftor on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Deutivacaftor/tezacaftor/vanzacaftor (Primary) ; Rosuvastatin (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 11 Feb 2026 Status changed from not yet recruiting to recruiting.
- 27 Jan 2026 New trial record